Peanut hypersensitivity
Drug research and approvals for peanut hypersensitivity: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 20 studies of peanut hypersensitivity are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 20
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting now
Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗- A 52-week Study of Remibrutinib in IgE-mediated Food AllergyNCT07768371 · Phase 3 · Novartis Pharmaceuticals · starts Aug 27, 2026
- Study of Oral Food Challenge Biomarkers (SAFER)NCT07279467 · Not reported · National Institute of Allergy and Infectious Diseases (NIAID) · starts Aug 20, 2026
- Efficacy of Tezepelumab in Peanut Oral ImmunotherapyNCT07015996 · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Jul 27, 2026
- Single Ascending and Multiple Ascending Dose Study of LCA-0061NCT07701954 · Phase 1 · Lycia Therapeutics, Inc. · starts Jun 26, 2026
- UKK-0018 as an Immunotherapeutic for Treatment of Peanut AllergiesNCT07349212 · Phase 1 / Phase 2 · Ukko Inc · starts Feb 18, 2026
- A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral…NCT07359183 · Not reported · Murdoch Childrens Research Institute · starts Jan 13, 2026
- Study of ENP-501 in Peanut-Allergic and Non-Allergic ParticipantsNCT07117669 · Phase 1 / Phase 2 · N-Fold, LLC · starts Dec 16, 2025
- Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients…NCT07287033 · Phase 1 · Mabylon AG · starts Dec 6, 2025
- Pathway to Peanut ToleranceNCT07592780 · Not applicable · Chinese University of Hong Kong · starts Nov 15, 2025
- Expecting Mother's Study of Consumption or Avoidance of Peanut and EggNCT06260956 · Not applicable · University of Rochester · starts Aug 1, 2025
Drug pipeline
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indicationsApproved 1
- Defatted powder of arachis hypogaea l., semen (peanuts)Food allergy desensitisation
Phase 3 1
- OmalizumabIg epsilon chain C region inhibitor
Phase 2 7
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- Oatmeal, colloidal
- TerfenadineHistamine H1 receptor antagonist
- KetotifenHistamine H1 receptor antagonist
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- LigelizumabIg epsilon chain C region inhibitor
- EtokimabInterleukin-33 binding agent
Phase 1 or earlier 1
How its trials ended
132 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 55% met their primary endpoint, 5% missed it and 40% stopped early.
- Completed, result not reported4937%
- Ongoing3325%
- Met its primary endpoint2217%
- Status unknown108%
- Stopped: other or unclear86%
- Stopped: enrollment or feasibility43%
- Stopped: sponsor or business decision32%
- Missed its primary endpoint22%
- Stopped: funding11%
Medicines authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Dec 17, 2020 | PalforziaDefatted powder of Arachis hypogaea L., semen (peanuts) | Stallergenes | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA